Effect of Anti-CD303 Antibodies in Autoimmune Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-20

Study Completion Date

2019-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The pathogenic role of type I interferons (IFNs) in the development of different autoimmune diseases has been extensively described in the literature. Since plasmacytoid dendritic cells (pDCs) are the main source of type I IFNs, there is evidence of the involvement of pDCs in autoimmune diseases. The CD303 surface protein (also called BDCA-2) is specifically expressed by the pDCs.

The hypothesis leading to the realization of this study is to observe, in vitro, an inhibition of the secretion of the type I IFNs by pDCs in the peripheral blood in patients with autoimmune disease, thanks to the action of the anti-CD303 antibody Developed by the LFB Group, which could reduce the inflammatory response and improve patients with autoimmune disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders

NCT07037732

Autoimmune Cytopenia Connective Tissue Disorder Systemic Vasculitis

RECRUITING

Analysis of B Cells From Autoimmune Individuals

NCT02747277

Lupus Erythematosus Rheumatoid Arthritis Type 1 Diabetes

COMPLETED

Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases

NCT06757426

Autoimmune Diseases Inflammatory Diseases

NOT_YET_RECRUITING

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515

Systemic Lupus Erythematosus

COMPLETED PHASE2

Anti-infection of Low-does IL-2 in SLE

NCT02932137

Systemic Lupus Erythematosus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient

Group Type EXPERIMENTAL

Monoclonal anti-cd303 antibody

Intervention Type BIOLOGICAL

Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monoclonal anti-cd303 antibody

Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study data collection procedures
* Patient followed in the department of internal medicine of CHU Lille
* Patient with one of the following autoimmune disease, defined according to international criteria: systemic lupus erythematosus, systemic sclerosis, Gougerot-Sjögren syndrome and idiopathic thrombocytopenic purpura
* Being socially insured

Exclusion Criteria

* Overlapping syndrome with another autoimmune disease
* Age ≤18 years
* Pregnant or nursing women
* People in emergencies
* Person incapable of consent
* Persons deprived of liberty
* Persons without social security cover

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No